Surrozen's President & CEO, Craig Parker, discusses how the expertise, resources and flexibility of Lonza have been fundamental in advancing its novel and complex bispecific antibody candidates that target the WNT pathway.

You may also be interested in:
Mammalian
Cell Line Development
Clinical Supply Services
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.
Latest briefing from the Knowledge Center
Technical/Service brief
Room to Grow: Exploring the Capabilities of 15,000L Microbial Manufacturing
Scaling microbial processes requires more than capacity - it demands precision, flexibility, and...
Technical/Service brief
Rapid Cocoon® CAR-T: rapid manufacturing of CAR-T cells with integrated selection in the Cocoon®...
Integrated magnetic separation capabilities enrich for a pure T cell input To enable rapid...
DPS
White paper
Industry-backed, data-driven approaches to enhancing container closure integrity
Container closure integrity (CCI) is central to ensuring product quality and patient...
tech operating dryer
Webinar (on-demand)
Dry powder for intranasal delivery
This webinar is your chance to get ahead in the world of drug delivery. We're...
Presentation (on-demand)
Overcoming biotherapeutic protein expression challenges with advanced vector technology for a range...
The development of biotherapeutic products is complex and the growing prevalence of next-generation...
Webinar (on-demand)
Industrialization of AAV manufacturing with Xcite® transient and stable production platforms
In this presentation, industry experts Suparna Sanyal and Peng Wang from Lonza take you deep into...
Lonza_Bend_EarlyPhaseLab33
Article
Streamlining early phase drug development with continuous flow technologies
As small molecule complexity increases, early-stage development faces new challenges that demand...
Poster
Designing a Plug-and-Play System to Produce Engineered Extracellular Vesicles
Extracellular vesicles (EVs), including exosomes, are being studied extensively and have emerged as...
Poster
Plasmid Engineering and Process Development to Improve Self-Complementary AAV Productivity
Self-complementary AAV (scAAV) vectors were developed by mutating one of the ITRs to form...
Poster
Development of high-performing stable producer cell lines for therapeutic AAV vector manufacturing
Attributed to their safety profiles and transduction efficiencies, recombinant Adeno-associated...
Poster
Adeno-associated virus characterization using nanopore long read sequencing and analysis
Recombinant adeno-associated virus (rAAV) has become a leading vector for in vivo gene delivery. The...
Poster
Large-Scale High Titer Lentiviral Production Using Lonza's Suspension Transient Transfection...
Lentivirus vector (LVV) is a major player in cell and gene therapies. It efficiently transduces both...